Literature DB >> 7585609

ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer.

J Szöllösi1, M Balázs, B G Feuerstein, C C Benz, F M Waldman.   

Abstract

Amplification of the ERBB-2 (HER-2/neu) gene is accompanied by overexpression of its cell surface receptor product, p185HER-2. Heterogeneity has been observed for both the gene copy number and the level of overexpression of its protein product. To better understand their relationship, correlation between the level of cellular expression of p185HER-2 and ERBB-2 gene amplification was studied in four human breast cancer cell lines (BT-474, SK-BR-3, MDA-453, and MCF-7) and in a primary human breast tumor sample. The relative expression of p185HER-2 was measured by immunofluorescence by using flow and/or image cytometry while correlated DNA analysis was performed on the same cells by fluorescence in situ hybridization to determine ERBB-2 gene and chromosome 17 copy numbers. Marked heterogeneity was observed in both protein expression and ERBB-2 copy number. Despite this heterogeneity, and in accordance with previous studies, the average levels of p185HER-2 expression correlated well with average ERBB-2 gene copy numbers in the four lines examined (r = 0.99). When the relationship between copy number and protein expression was studied on a cell-by-cell basis, p185HER-2 expression correlated with both the absolute number of ERBB-2 gene copies/cell (r = 0.59-0.63) and chromosome 17 copy number (r = 0.45-0.61). It is of interest that there was weak or no correlation between p185HER-2 protein expression and the ERBB-2 copy number:chromosome 17 copy number ratio (r = 0.0-0.25). In more than one-half of cells expressing a high level of p185HER-2, the chromosome 17 copy number was high (two or three times the average copy number), whereas < 2% of an unselected population had a high chromosome 17 copy number. Bromodeoxyuridine incorporation indicated that the S-phase-labeling index was homogeneous across various p185HER-2-expressing subpopulations in the SK-BR-3 cell line. Analysis of the primary breast tumor sample showed results similar to the cell lines, supporting the strong possibility of a mechanistic link among p185HER-2 overexpression, ERBB-2 amplification, and high chromosome 17 copy number.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7585609

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  Expression of molecular biomarkers in primary breast tumors implanted into a surrogate host: increased levels of cyclins correlate with tumor progression.

Authors:  G Wani; I Noyes; G E Milo; S M D'Ambrosio
Journal:  Mol Med       Date:  1997-04       Impact factor: 6.354

2.  On the evidence for ESR1 amplification in breast cancer.

Authors:  Frederik Holst; Cathy B Moelans; Martin Filipits; Christian F Singer; Ronald Simon; Paul J van Diest
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

3.  [Intratumoral heterogeneity of HER2 status in breast carcinoma].

Authors:  C Ohlschlegel; K Zahel; D Kradolfer; M Hell; W Jochum
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

4.  Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.

Authors:  George Somlo; Sean K Lau; Paul Frankel; H Ben Hsieh; Xiaohe Liu; Lixin Yang; Robert Krivacic; Richard H Bruce
Journal:  Breast Cancer Res Treat       Date:  2011-04-16       Impact factor: 4.872

5.  Single-Cell Intravital Microscopy of Trastuzumab Quantifies Heterogeneous in vivo Kinetics.

Authors:  Ran Li; Adel Attari; Mark Prytyskach; Michelle A Garlin; Ralph Weissleder; Miles A Miller
Journal:  Cytometry A       Date:  2019-08-19       Impact factor: 4.355

6.  Revealing tumor heterogeneity of breast cancer by utilizing the linkage between somatic and germline mutations.

Authors:  Meng Zou; Rui Jin; Kin Fai Au
Journal:  Brief Bioinform       Date:  2019-11-27       Impact factor: 11.622

7.  Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction.

Authors:  U Lehmann; S Glöckner; W Kleeberger; H F von Wasielewski; H Kreipe
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

8.  Certified DNA Reference Materials to Compare HER2 Gene Amplification Measurements Using Next-Generation Sequencing Methods.

Authors:  Chih-Jian Lih; Han Si; Biswajit Das; Robin D Harrington; Kneshay N Harper; David J Sims; Paul M McGregor; Corinne E Camalier; Andrew Y Kayserian; P Mickey Williams; Hua-Jun He; Jamie L Almeida; Steve P Lund; Steve Choquette; Kenneth D Cole
Journal:  J Mol Diagn       Date:  2016-07-25       Impact factor: 5.568

9.  Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models.

Authors:  Sharon L Longo; David J Padalino; Sandra McGillis; Kirstin Petersen; Hartmut Schirok; Oliver Politz; Gregory W Canute; Dawn E Post
Journal:  Invest New Drugs       Date:  2011-12-29       Impact factor: 3.850

10.  Differential expression of EphA5 protein in gastric carcinoma and its clinical significance.

Authors:  Wei Zhang; Xue Wei; Shuwei Guo; Jiandong Wang; Jing Liu; Hai Wang
Journal:  Oncol Lett       Date:  2019-03-19       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.